Best in class? Eli Lilly claims a lead role awaits its CDK 4/6 drug abemaciclib after PhIII success
The pharma giant says their drug abemaciclib garnered promising data in an interim analysis of MONARCH-3, a breast cancer trial that matched their drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.